Alcon Laboratories, Inc.

Other

Alcon Manufacturing, Ltd.

Alcon Universal Ltd.

Billie M York

Jon C Nixon

John M Yanni

Thomas R Dean

Louis DeSantis, Jr

Joseph M DeFaller

Mark T DuPriest

Abbot F Clark

Jeffrey S Kiel

Stella M Robertson

Ralph P Stone

Yoseph Yaacobi

Salomon Z Langer

Icilio A Cavero

Louis M Desantis, Jr

Mark T Dupriest

David Allen Marsh

Evan P Kyba

Betty R House

Craig B Struble

Karen C Sams

David C Dahlin

Rodney P Horn

Disclosed is a method and apparatus for delivering a drug formulation to a human eye. The method includes the steps of inserting the apparatus below the Tenon's capsule and above the sclera at a point posterior to the limbus of the eye and injecting the drug formulation to form a drug depot on an outer surface of the sclera. The apparatus includes a cannula having a distal portion, a proximal portion, and a bend separating the distal portion and the proximal portion. The distal portion has a radius of curvature substantially equal to a radius of curvature of the globe of the eye. A tangent of the distal portion at the bend is disposed at an angle no more than about 56 degrees with respect to the proximal portion.

Sub-tenon drug delivery

Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.

Brinzolamide and brimonidine for treating glaucoma

Brinzolamide and brimonidine for treating ocular conditions

Compositions for disinfecting fabric and preventing spread of contamination are disclosed. Methods for their use are also contemplated.

Compositions and method for disinfecting fabric

The intraocular use of combinations of stromal cell growth stimulators (e.g., TGF-.beta.) and antimetabolites (e.g., mitomycin C) in connection with glaucoma filtration surgery is described. The combination is applied to the surgical site to attract, mitogenically activate, and neutralize the potential for extracellular matrix synthesis leading to scar formation by stromal cells. Without such treatment, the formation of scar tissue may lead to impairment of the outflow of aqueous humor at the surgical site, particularly the fistula. The mitogenic activation of the stromal cells makes these cells susceptible to the anti-metabolites. This enables the antimetabolites to suppress the proliferation of the fibroblasts and other associated stromal cells to a much greater extent, relative to the proliferation seen when the metabolites alone are utilized. The increased suppression of the proliferation and metabolism of these cells results in a significant improvement in the ability to prevent or retard the formation of scar tissue, and thereby reduces the incidence of fistula closure following glaucoma filtration surgery.

Use of growth factor and antimetabolite combination to prevent or retard

The intraocular use of combinations of lens epithelial cell growth stimulators (e.g., TGF-.beta.) and antimetabolites (e.g., mitomycin C) is described. The combination is applied to the capsular bag to prevent or retard the formation of secondary cataracts following cataract surgery. The lens epithelial cell stimulators activate DNA synthesis in dormant lens epithelial cells, and thereby make those cells susceptible to the anti-metabolites. This enables the antimetabolites to suppress the proliferation of lens epithelial cells to a much greater extent, relative to the proliferation observed when the metabolites alone are utilized. The increased suppression of the growth of lens epithelial cells results in a significant improvement in the ability to prevent or retard the formation of opacities on the lens capsule (i.e., secondary cataracts).

Compositions containing, and methods for controlling intraocular pressure with, substantially pure apraclonidine are disclosed.

Substantially pure apraclonidine

Disclosed are novel compositions comprising mixtures useful to treat the metabolically impaired and to improve patient compliance. Included are non-racemic mixtures of certain chiral spirofluorenehydantoins. Methods of use to treat glucose toxicity and complications arising from diabetes mellitus are also disclosed.

Compositions and methods for the treatment of the metabolically impaired

The intraocular use of TGF-.beta..sub.3 in connection with glaucoma filtration surgery is described. A composition containing TGF-.beta..sub.3 is applied to the surgical site to suppress the production and/or alter the composition of extracellular matrix synthesized by fibroblasts at the surgical site, and thereby reduce the formation of scar tissue and consequent impairment of the outflow of aqueous humor through a fistula created during the surgery.

Use of TGF-.beta.3, to prevent or retard fistula closure following

The use of TGF-.beta..sub.3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-.beta..sub.3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-.beta..sub.3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.

Use of TGF-.beta..sub.3 to reduce the formation of scar tissue in

Compounds having beta-2 adrenergic agonist activity and the use of these compounds in controlling intraocular pressure are disclosed. The compounds are believed to be useful in controlling intraocular pressure by increasing the outflow of aqueous humor. The compounds are considered to be less likely to cause cardiovascular side effects and various other side effects associated with stimulation of beta-1 receptors, relative to epinephrine.

B.sub.2 adrenegic agonists and use thereof in the treatment of glaucoma

A method of controlling intraocular pressure by nonchronic, topical administration of a clonidine derivative immediately prior and post trauma to the affected eye.

Control of post-surgical intraocular pressure using clonidine derivatives

Compositions of an antiallergic compound and an antihistamine for preventing and treating ophthalmic allergic responses are disclosed. Methods for preventing and treating ophthalmic allergic responses with the compositions are also disclosed.

Methods using antiallergics and antihistamines

Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia, in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome.

Spiro-tricyclicaromatic succinimide derivatives

Disclosed are 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and their N-acyl and N-alkyl derivatives. Also disclosed are processes for preparing the disclosed compounds; pharmaceutical compositions comprising such compounds; and a method of treatment comprising administering such compounds and compositions when an antihypertensive effect or radioprotective effect is indicated.

Growing community of inventors

Fort Worth, TX, United States of America

Billie M York